Vaccinex Inc Stock Price, News & Analysis

Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.

Vaccinex, Inc. (VCNX) generates frequent news as a clinical-stage biotechnology company advancing pepinemab, a monoclonal antibody targeting semaphorin 4D (SEMA4D), in neurodegenerative disease and oncology. News coverage for VCNX often centers on clinical trial updates, scientific presentations, and partnering activity related to its lead programs.

Investors and researchers following VCNX news can expect detailed reports on the Phase 1b/2 SIGNAL-AD trial in Alzheimer’s disease, including biomarker and cognitive data in Mild Cognitive Impairment and mild dementia. Releases also describe findings from a prior randomized Phase 2 study in Huntington’s disease and how these results inform the company’s broader neurodegenerative strategy.

On the oncology side, Vaccinex news frequently highlights data from the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer and a Phase 1b/2 trial in metastatic pancreatic adenocarcinoma, where pepinemab is combined with immune checkpoint inhibitors such as KEYTRUDA and BAVENCIO. Company updates discuss how pepinemab appears to promote mature tertiary lymphoid structures in tumors and may enhance the clinical activity of checkpoint therapies, particularly in HPV-negative and PD-L1-low head and neck cancer and metastatic melanoma.

Additional VCNX news items cover collaborations and project agreements using the ActivMAb antibody discovery platform with multiple biopharmaceutical partners, as well as corporate developments such as financing transactions and changes in stock listing status, including the transition from Nasdaq to OTC quotation. For users tracking Vaccinex, this news stream offers ongoing insight into trial progress, scientific rationale, partnerships and regulatory or listing milestones related to the VCNX symbol.